.Nature Medicine, Published online: 03 September 2024 doi:10.1038/ s41591-024-03223-zThis Standpoint calls for incorporation of people with MASLD as well as size of liver results in cardio-- kidney-- metabolic trials, when records recommend mechanistically conceivable advantages and also scientific safety-- and also outlines factors to consider for trial design as well as regulative approval.